Earnings ·
Abbott raises full-year adjusted diluted EPS guidance to $5.45-$5.60 on 13% sales growth
ABTAbbott Laboratories
Abbott Laboratories reported second-quarter 2026 results with reported sales growth of 13.0 percent and adjusted diluted EPS of $1.31. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. Abbott returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases. Abbott Laboratories is a global healthcare leader providing diagnostics, medical devices, nutritionals, and branded generic medicines.